MetaVia Begins Phase 1 Part 3 Clinical Trial for DA-1726
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2026
0mins
MetaVia announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.510
Low
40.00
Averages
47.50
High
55.00
Current: 1.510
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction Opportunity: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future developments through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in obesity treatment, showing promising results in clinical trials for glucose control and waist reduction, which could provide a significant competitive advantage in the market.
- Promising Drug Candidate: Vanoglipel, as a potential first-in-class drug, has shown direct hepatic action and metabolic improvement in clinical studies, and if successfully launched, it could open new revenue streams for the company and elevate its market position.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance the company's visibility.
- Real-Time Interaction: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future prospects through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in Phase 1 trials for obesity treatment, potentially outperforming existing GLP-1 receptor agonists, which could significantly enhance the company's competitive position in the biotechnology sector if successful.
- Potential First-in-Class Drug: Vanoglipel, targeting GPR119, has shown positive metabolic effects on glucose and lipid control in preclinical studies, and if validated in subsequent clinical trials, it could open new market opportunities for the company.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Market Opportunities: Biotech companies are experiencing significant pre-market activity on Tuesday, driven by plans for market launches, acquisitions, financing deals, and AI training program launches, indicating potential investment opportunities.
- Notable Gains: Regentis Biomaterials Ltd. (RGNT) saw its stock price surge by 124% to $2.91, reflecting strong market confidence in its future growth and likely attracting more investor interest.
- Significant Losses: Park Ha Biological Technology Co., Ltd. (BYAH) experienced a 39% decline in its stock price to $1.61, indicating market concerns about its business outlook, which may lead investors to reassess their investment strategies.
- Increased Volatility: The price volatility among biotech stocks is heightened, particularly in the context of acquisitions and financing deals, prompting investors to closely monitor market dynamics to seize potential investment opportunities and risks.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented that the 48 mg cohort of DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau, indicating the drug's potential in obesity treatment and possibly enhancing future market acceptance.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, laying a solid foundation for its further clinical development and boosting investor confidence.
- Combination Therapy Effects: The combination of vanoglipel with resmetirom showed a 23.6% weight reduction in mouse models, along with significant improvements in liver fat and inflammation markers, indicating its potential therapeutic value in metabolic diseases and possibly opening new market opportunities for MetaVia.
- Future Development Plans: MetaVia plans to release results from higher-dose DA-1726 clinical trials in Q4 2026, continuing to advance its research in obesity and metabolic diseases, demonstrating the company's long-term commitment and confidence in its product pipeline.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction Opportunity: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future developments through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in obesity treatment, showing promising results in clinical trials for glucose control and waist reduction, which could provide a significant competitive advantage in the market.
- Promising Drug Candidate: Vanoglipel, as a potential first-in-class drug, has shown direct hepatic action and metabolic improvement in clinical studies, and if successfully launched, it could open new revenue streams for the company and elevate its market position.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance the company's visibility.
- Real-Time Interaction: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future prospects through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in Phase 1 trials for obesity treatment, potentially outperforming existing GLP-1 receptor agonists, which could significantly enhance the company's competitive position in the biotechnology sector if successful.
- Potential First-in-Class Drug: Vanoglipel, targeting GPR119, has shown positive metabolic effects on glucose and lipid control in preclinical studies, and if validated in subsequent clinical trials, it could open new market opportunities for the company.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Market Opportunities: Biotech companies are experiencing significant pre-market activity on Tuesday, driven by plans for market launches, acquisitions, financing deals, and AI training program launches, indicating potential investment opportunities.
- Notable Gains: Regentis Biomaterials Ltd. (RGNT) saw its stock price surge by 124% to $2.91, reflecting strong market confidence in its future growth and likely attracting more investor interest.
- Significant Losses: Park Ha Biological Technology Co., Ltd. (BYAH) experienced a 39% decline in its stock price to $1.61, indicating market concerns about its business outlook, which may lead investors to reassess their investment strategies.
- Increased Volatility: The price volatility among biotech stocks is heightened, particularly in the context of acquisitions and financing deals, prompting investors to closely monitor market dynamics to seize potential investment opportunities and risks.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented that the 48 mg cohort of DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau, indicating the drug's potential in obesity treatment and possibly enhancing future market acceptance.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, laying a solid foundation for its further clinical development and boosting investor confidence.
- Combination Therapy Effects: The combination of vanoglipel with resmetirom showed a 23.6% weight reduction in mouse models, along with significant improvements in liver fat and inflammation markers, indicating its potential therapeutic value in metabolic diseases and possibly opening new market opportunities for MetaVia.
- Future Development Plans: MetaVia plans to release results from higher-dose DA-1726 clinical trials in Q4 2026, continuing to advance its research in obesity and metabolic diseases, demonstrating the company's long-term commitment and confidence in its product pipeline.
See More
